Monday, May 13, 2013

• pSivida Corp. Reports Third Quarter Fiscal Year 2013 ResultsBusiness Wire( (Mon, May 13)

Tuesday, May 7, 2013

• pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient TreatedBusiness Wire( (Tue, May 7)

Monday, May 6, 2013

• pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call InformationBusiness Wire( (Mon, May 6)

Wednesday, May 1, 2013

• pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013Business Wire( (Wed, May 1)

Monday, April 29, 2013

• pSivida Reports ILUVIEN® Available in UKBusiness Wire( (Mon, Apr 29)

Wednesday, April 17, 2013

• pSivida Corp. President and CEO, Dr. Paul Ashton Publishes Blog Post Titled ''Transformational Change and Ophthalmology''Accesswire( (Wed, Apr 17)

Wednesday, April 10, 2013

• pSivida Announces Launch of New Online Corporate Communication ChannelsBusiness Wire( (Wed, Apr 10)

Thursday, April 4, 2013

• pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical CompanyBusiness Wire( (Thu, Apr 4)

Monday, April 1, 2013

• pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular EdemaBusiness Wire( (Mon, Apr 1)

Wednesday, March 27, 2013

• pSivida Corp - Transformational Change via Strategic Drug DeliveryAccesswire( (Wed, Mar 27)

Friday, March 22, 2013

• pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European LaunchBusiness Wire( (Fri, Mar 22)

Wednesday, March 20, 2013

• pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development ConferenceBusiness Wire( (Wed, Mar 20)